Overview

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Status:
Recruiting
Trial end date:
2028-05-23
Target enrollment:
Participant gender:
Summary
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies.
Phase:
Early Phase 1
Details
Lead Sponsor:
He Huang
Collaborator:
Yake Biotechnology Ltd.